In this work, a modified version of the 44 amino acid human growth hormonereleasing hormone (hGHRH(1-44)) containing an N-terminal proline extension, a valine residue in position 14, and a C-terminus amidation (sequence: PYADAIFTNSYRKVVLGQLSARKLLQDIMSRQQGESNQERGARARL-NH 2 ) has been identified in a confiscated product by liquid chromatography-high resolution mass spectrometry (LC-HRMS). Investigation of the product suggests also an incomplete C-term amidation.
INTRODUCTION
The use of peptide-based doping agents has become increasingly popular during the last years [1] . A relevant phenomenon for this class of substances is represented by unapproved peptide formulations [2] [3] [4] [5] [6] . According to the Prohibited List of substances and methods of the World Anti-Doping Agency (WADA) [7] , any pharmacological substance without current approval by any governmental regulatory health authority for human therapeutic use, is prohibited.
Unapproved drugs are generally not accessible through legal channels of distributions, but several cases have already demonstrated how they can find their way into black markets [2] [3] [4] [5] [6] 8, 9] . This phenomenon represents a big concern for public health, since these preparations are often prepared with no respect for good manufacturing practice, with lack or even total absence of information on composition. Moreover, these peptides do not usually undergo a complete toxicological evaluation (e.g.: TB-500) [6] , and therefore the risks associated with the intake are unpredictable.
In sport drug testing, identification of new peptides with performing-enhancing properties is a first important step towards the development of effective detection methods for monitoring their misuse in sports [10, 11] . In this context, collaboration between controlling authorities and laboratories has a crucial role in the battles against illegal trade of peptide hormones.
Recently, an unknown preparation, consisting of an unlabeled vial containing lyophilized powder (Figure 1) , was confiscated by Belgian Customs authorities and then delivered to our laboratory for identification. The product was characterized by ultra-high performance liquid chromatography/high-resolution mass spectrometry (UHPLC-HRMS).
EXPERIMENTAL Chemicals
Acetonitrile and water (LC grade) were purchased from BioSolve (Lexington MA, USA). Glacial acetic acid was purchased from Merck (Darmstadt, Germany). 
Liquid chromatography
The UHPLC system consisted of an Accela LC (Thermo Scientific, Bremen, Germany) equipped with degasser, Accela 1250 pump, autosampler thermostated at 10°C and a heated column compartment. LC separation was performed using a Zorbax SB-C8, 2.1 x 50 mm and 1.8 µm particle size from Agilent Technologies (Böblingen, Germany) thermostated at 25°C. The mobile phases were 0.2% formic acid in water (A) and 0.2% formic in acetonitrile (B). The gradient program was as follows: 100% A for 5 min, then decreased linearly to 0% in 8.0 min, and held at 0% for 2 min followed by an increase to the initial concentration of 100% A in 0.1 min.
Equilibrium time was 5 min resulting in a total run time of 20 min. The flow rate was set constant at 250 µL/min and the injection volume was 10 µL.
High-resolution mass spectrometry
HRMS characterization was performed using a Q-Exactive benchtop, Orbitrap™-based mass spectrometer (Thermo Scientific, Bremen, Germany) operated in positivenegative polarity switching mode and equipped with a heated electrospray ion source (HESI). Nitrogen sheath gas flow rate and auxiliary gas were set at 60 and 30 (arbitrary units), respectively. The capillary temperature was 350°C, the spray voltage 
Data analysis
ProMass software from Thermo Fisher (Bremen, Germany) was used for spectral deconvolution. Protein Prospector v 5.10.19 was used to predict both trypsin digestion products and fragmentation of peptides for de novo sequencing [12] .
RESULTS

Identification of [Pro1, Val14]-hGHRH
HRMS is an ideal tool for identification of peptidic compounds due to the possibility to determine the amino acid sequence of a peptide based upon its MS/MS spectrum.
Preliminary analysis constisted of direct injection for FSMS analysis. In order to obtain better peptide sequencing, the peptide was incubated with the proteolytic enzyme trypsin. Tryptic digestion allowed for the formation of smaller subunits of the peptide (MW < 2000 Da) which could be easily sequenced for the identification of the intact peptide. Tryptic product peptides that were identified are all summarized on Table 1 . As shown in Figure 3 for six representative peptides, de novo sequencing from MS/MS spectra of tryptic products generated by enzymatic digestion of the native peptide provided identification of the unknown substance as a 46-aa modified version of human GHRH(1-44, corresponding to the sequence PYADAIFTNSYRKVVLGQLSARKLLQDIMSRQQGESNQERGARARL and to an exact monoisotopic mass of 5233,7637 Da, confirming the value obtained from spectral deconvolution of the native peptide. The peptide has a proline residue at the N-terminus (Figure 3a and 3b) , a valine residue in position 14 (Figure 3b and 3c ) and a C-term amidation which are not present in hGHRH and it will be further referred as
The valine in position 14 was the most surprising finding, since it was inserted as an additional amino acid and not, as expectable, in substitution of an amino acid (perhaps arginine or lysine, sensible to enzymatic degradation). On the other hand, N-terminal proline extension and C-terminal amidation have been described for GHRH analogues [13, 14] Cleavage sites for [Pro1, Val14]-hGHRH were the carboxyl side of Arg 12,22,31,39,43 , and Lys 13,23, which are typical cleavage sites for trypsin. Digestion products with missing cleavages were also detected (due to incomplete digestion); however, these peptides provided further confirmation of the sequence.
C-terminus: an incomplete amidation?
Analysis of the tryptic products, particularly of the product aa 44-46, revealed the presence of both free and amidated C-terminus. As shown in Figure 4 Δppm= -2.5) (Figure 4d ). The ratio between the area of the peaks indicates that the free peptide is significantly more abundant than the amidated. Unfortunately, no appropriate reference standards were available to provide a more precise determination.
As trypsin does not have deamidating activity, the free form could not be generated during the digestion. Traces of the amidated form (monoisotopic mass= 5232.7560)
were also detected in the native peptide (Figure 4e and 4f ).
Amidation, a common strategy to improve the pharmacokinetics properties of a peptidic drug, is generally performed in the last stages of the synthesis. Moreover, amidation is present in other GHRH analogues [4] . This finding suggests an incomplete amidation of the peptide during the manufacturing process. This is a clear example of the lack of quality controls typically associated to the production of black market peptides.
Misuse and detection of [Pro1, Val14]-hGHRH
The human growth hormone-releasing hormone (GHRH) is a 44 amino acid hypothalamic peptide (sequence:
(YADAIFNTSYRKVLGQLSARKLLQDIMSRQQGESNQERGARARL) that stimulates GH production and release [14] . GHRH analogues are considered as prohibited substances according to section S2 of WADA List (peptide hormones, growth factors and related substances) [7] . To the best of our knowledge, [Pro1, Val14]-hGHRH-NH 2 has not been approved for any clinical application.
There is reason to believe that [Pro1, Val14]-hGHRH might be marketed as performance-enhancing drug. Indeed, similar to other several other analogues of GHRH(1-44) and GHRH(1-29) (tesamorelin, sermorelin, CJC-1293 and CJC-1295) [4] , [Pro1,Val14]-hGHRH appears to find its way to black market and is classified by the marketers as a performance-enhancing drug. GHRH analogues appear to be attractive especially to some communities such as bodybuilding and fitness.
Obviously, no pharmacokinetics data are available for [Pro1, Val14]-hGHRH, but very low urinary and plasmatic concentrations (sub ng/mL) and short half-life can be expected. However, due to its similarity to other GHRH analogues, currently existing methods based on immunoaffinity purification followed by LC-MS detection should theoretically be able to monitor its abuse [10] .
FIGURE AND TABLE CAPTION
Figure 1
The product confiscated by Belgian Customs.
Figure 2
Full scan spectrum of the unknown peptide. 
Table 1
List of tryptic peptides detected after digestion,including those with missing cleavages.
